The role of inhaled and/or nasal corticosteroids on the bronchodilator response by Lee, Ju Kyung et al.
DOI: 10.3345/kjp.2010.53.11.951 
Korean J Pediatr 2010;53(11):951-956
Original article
951
The role of inhaled and/or nasal corticosteroids on 
the bronchodilator response
Purpose: To compare the profiles of the bronchodilator response 
(BDR) among children with asthma and/or allergic rhinitis (AR) and 
to determine whether BDR in these children is reduced by treatment 
with inhaled and/or nasal corticosteroid. 
Methods: Sixty-eight children with asthma (mean age, 10.9 years), 45 
children with comorbid asthma and AR (mean age, 10.5 years), and 
44 children with AR alone (mean age, 10.2 years) were investigated. 
After a 2-week baseline period, all children were treated with inhaled 
fluticasone propionate (either 100 or 250 µg b.i.d., tailored to asthma 
severity) or nasal fluticasone propionate (one spray b.i.d. in each 
nostril) or both, according to the condition. Before and 2 weeks after 
starting treatment, all children were evaluated with spirometry and 
bronchodilator testing. BDR was calculated as a percent change from 
the forced expiratory volume in 1 second (FEV1) at baseline. 
Results: The mean BDR was 10.3% [95% confidence interval (CI) 8.3-
12.4%] in children with asthma, 9.0% (95% CI 7.3-10.9%) in subjects 
with asthma and AR, and 5.0% (95% CI 4.1-5.9%) in children with AR 
alone (P<0.001). After treatment, the mean BDR was reduced to 5.2% 
(95% CI 4.2-6.3%) (P<0.001) in children with asthma and to 4.5% (95% 
CI 3.5-5.5%) (P<0.001) in children with asthma and AR. However, 
children with rhinitis showed no significant change in BDR after 
treatment, with the mean value being 4.7% (95% CI 3.7-5.8%) (P=0.597).
Conclusion: The findings of this study imply that an elevated BDR in 
children with AR cannot be attributed to nasal inflammation alone and 
highlights the close relationship between the upper and lower airways. 
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4). Pathophysiologically, they both show eosinophilic airway 
inflammation
2, 5). Clinically, their treatment options are similar
6). In 
co­morbid patients, effective treatment of AR also improves asthma 
symptoms
6, 7).
Introduction
There is a close relationship between asthma and allergic rhinitis 
(AR)
1­3). Epidemiologically, asthma and AR frequently coexist
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The Bronchodilator response (BDR) is usually characterized 
by an increase in forced expiratory volumes after inhalation of a 
bronchodilator. It is well known that airway hyperresponsiveness 
to nonspecific broncho­constrictors and a substantial BDR are 
important characteristics of asthma
8). The Assessment of the BDR 
in patients with asthma is widely used in clinical practice. Generally, 
the BDR is elevated in asthmatic patients
9­12). In patients with AR, 
BDR is not used as a routine test. However, recent studies reported 
elevated BDR in some AR patients who had neither a history nor 
clinical symptoms of asthma
13, 14).
In asthma, controller medication reduces airway inflammation, 
relieves symptoms and improves lung function
15). Regular inhalation 
of corticosteroids are reported to reduce BDR in asthmatic patients
16, 
17). In patients with AR, intranasal corticosteroids are recommended 
as a first­line therapy to reduce upper airway inflammation and to 
relieve rhinitic symptoms, especially nasal congestion
18). However, 
little is known about the changes in the BDR in patients with AR 
after regular administration of intranasal corticosteroids.
This study was conducted to compare BDR in children with 
asthma and/or AR and to investigate the effect of inhaled and nasal 
corticosteroids on the BDR in these patients. 
Materials and methods
1. Subjects 
One hundred and fifty­seven children with asthma and/or AR 
(mean age, 10.6 years) were enrolled in this study during the period 
between June 2005 and January 2010. All subjects attended the 
allergy clinic at Seoul National University Children’s Hospital. 
Asthma was diagnosed by a physician with the history of recurrent 
episodic symptoms (cough, wheezing and dyspnea) and symptom­
free intervals. All asthmatic children had airway hyperresponsiveness 
defined by as a provocative concentration of methacholine causing 
a 20% fall in forced expiratory volume in 1 second (FEV1) (PC20) 
of <16 mg/mL. They had mild to moderate asthma and needed 
intermittent use of β 2­agonists with or without continuous use of low­
dose inhaled corticosteroids to control their asthma symptoms. AR 
was diagnosed with the patient’s history, rhinologic examination, 
and skin­prick test. Children with AR had recurrent symptoms 
of sneezing, rhinorrhea, and nasal stuffiness or itching during 
the preceding year. In rhinitic children, pallor or swelling of the 
nasal mucosa and turbinates was a frequent finding. They needed 
intermittent use of oral anti­histamines with or without continuous 
use of nasal corticosteroids to control their rhinitic symptoms. All 
children with AR regardless of co­morbid asthma were positive for 
skin­prick test. Clinical examination and chest radiograph were 
performed to exclude other causes of wheeze or clinically significant 
medical disorders apart from asthma or AR. 
Parents and children provided written informed consent for their 
participating in the study. The Institutional Review Board of our 
hospital approved the study protocol. 
2. Study Design 
Subjects were divided into three groups according to their 
diagnosis : children with asthma, with co­morbid asthma and AR, 
and with AR. All subjects had a 2­week baseline period, followed 
by a treatment period. During the baseline period, all asthmatic 
children were asked to discontinue their controller medication, if 
used, and to use  β 2­agonists on demand. In the baseline period, 
all rhinitic children were asked to discontinue oral anti­histamines 
and nasal corticosteroids. In the treatment period, children with 
asthma were asked to receive inhaled corticosteroids, children with 
AR to receive nasal corticosteroids, and children with co­morbid 
asthma and AR to receive both inhaled and nasal corticosteroids. 
All asthmatic children regardless of co­morbid AR used inhaled 
fluticasone propionate (FP) (Seretide Diskus
TM, GlaxoSmithKline, 
Middlesex, UK) twice a day. The dose of inhaled FP was tailored 
to asthma severity, either 100 or 250 μ g. All children with AR used 
nasal FP (Flixonase
TM, GlaxoSmithKline, Middlesex, UK) twice a 
day with one spray in each nostril.  
All children had undergone spirometry with the bronchodilator 
test at the end of the 2­week baseline period. Two weeks after 
starting treatment, they had undergone additional spirometry with 
bronchodilator test.
3. Skin prick test
The skin prick test was performed for the assessment of atopy. 
Thirteen common aeroallergens including house dust mites (Der­
ma  tophagoides pteronyssinus, Dermatophagoides farinae), animal 
danders (cat epithelia, dog epithelia), pollens (mugwort, ryegrass, 
ragweed, hazel, alder, oak), molds (Aspergillus fumigatus, Alternaria 
alternata), and cockroach (Blatella germanica) were used for the 
evaluation. 
Histamine and isotonic saline were used as positive and negative 
controls.  A mean wheal diameter of 3 mm or larger, in the absence 
of any reaction to saline solution, was considered a positive reaction. 
Atopy was defined as the presence of at least one positive reaction to 
a battery of 13 common airborne allergens. 
4. Bronchodilator test 
Forced expiratory volume in one second (FEV1) and forced vital 
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(Microspiro­HI 298, Chest, Tokyo, Japan) in accordance with 
the recommendations of the American Thoracic Society
19). The 
BDR is based on spirometric measurements before and after the 
administration of 200 μ g of salbutamol. Fifteen minutes after 
salbutamol inhalation, triplicate spirometry measurements were 
taken and the highest of the three FEV1 values was recorded. BDR 
was calculated as [(postbronchodilator FEV1-prebronchodilator 
FEV1)/prebronchodilator FEV1] ×100. Inhaled FP was withdrawn 
at least 24 hours before spirometry and bronchodilator test. When 
salbutamol was used as a rescue medicine, bronchodilator test was 
postponed until at least 6 hours after the last dose.  
5. Statistical analysis
Data are presented as means±SD. FEV1 and FVC values are 
expressed as percentages of predicted values. The changes in BDR 
and FEV1 of each group were assessed with a two­tailed Student’s 
paired t­test. To compare the degree of reduction in BDR between 
children with asthma and those with co­morbid asthma and AR, 
we used a two­tailed Student’s independent t­test. Spirometry 
measurements and the BDR of the three groups were compared by 
one­way ANOVA using Scheffe’s post hoc analysis. All P values less 
than 0.05 were considered statistically significant. All analyses were 
performed using statistical software SPSS version 12.0 (SPSS Inc., 
Chicago, IL, USA). 
Results 
The subjects’ descriptive characteristics are shown in Table 1. 
There were no statistically significant differences in height and age 
between the three groups.  
Spirometric measurements and BDR in the baseline period 
are summarized in Table 2. In prebronchodilator FEV1 and 
BDR, there were no statistically significant differences between 
children with asthma and those with co­morbid asthma and AR. 
Asthmatic children regardless of co­morbid AR showed a lower 
prebronchodilator FEV1 (P=0.004) and a higher BDR (P<0.001) 
than children with AR. Two weeks after starting treatment, 
there were improvements in both prebronchodilator FEV1 and 
postbronchodilator FEV1 in children with asthma regardless of 
co­morbid AR (Fig. 1). In children with asthma, after inhalation 
of FP, prebronchodilator FEV1 increased from 87.8±13.8% to 
94.7±12.1% (P<0.001), and postbronchodilator FEV1 also increased 
from 96.3±12.8% to  99.6±12.2% (P<0.001) in children with 
asthma. The BDR decreased from 10.4±8.5% to 5.3±4.2% in 
children with asthma (P<0.001). An analogous result has been 
observed in children with co­morbid asthma and AR. After 
medication with inhaled and nasal FP, both prebronchodilator 
FEV1 and postbronchodilator FEV1 increased from 85.0±11.1% 
to 91.2±10.0% (P=0.001) and from 92.1±10.1% to 95.1±9.7% 
(P=0.047), respectively. In children with co­morbid asthma and 
AR, the BDR decreased from 9.1±6.0% to 4.5±3.3% (P<0.001). 
To compare the degree of reduction in the BDR between these two 
groups, besides net change of BDR, we calculated the percentage 
change (Δ%) in the BDR with respect to values in the baseline 
period as following : Δ%BDR=[(BDR in the treatment period­ 
BDR in the baseline period)/BDR in the baseline period]×100. 
Net change of the BDR was not significantly different between 
Table 1. Demographic Characteristics of the Evaluated Patients (N=157)
Asthma Co-morbid asthma and AR AR
Population (n)
Sex (M/F)
Age (years)*
Height (cm)*
Atopy, n (%)
68
43/25
10.9±3.1
147.2±14.6
54 (79.4%)
45
39/6
10.4±2.1
144.3±14.1
45 (100%)
44
30/14
10.2±2.6
140.9±15.2
44 (100%)
*Mean±SD
Abbreviation : AR, allergic rhinitis
Table 2. Spirometric Values and Bronchodilator Response at the Baseline 
Asthma
Co-morbid asthma 
and AR
AR
preBD FEV1 (%predicted)
postBD FEV1 (%predicted)
BDR (%)
  87.8±13.8
  96.3±12.8
10.4±8.5
85.0±11.1
92.1±10.1
9.1±6.0
93.7±11.3*
98.4±12.4*
5.0±3.0*
Data are presented as means±SD. 
*P<0.05 vs. children with asthma and with co-morbid asthma and AR.
Abbreviations : AR, allergic rhinitis; preBD FEV1, prebronchodilator forced 
expiratory volume in one second; postBD FEV1, postbronchodilator forced 
expiratory volume in one second; BDR, bronchodilator response
P<0.001
P<0.001
P=0.597
at abseline after treatment
Fig. 1. BDR at baseline and after treatment with inhaled and/or nasal FP. 
BDR was reduced after treatment in children with asthma, irrespective 
of whether or not they had comorbid AR. There was no significant 
change in the BDR of children with AR alone. Abbreviations : BDR, 
bronchodilator response; FP, fluticasone propionate; AR, allergic rhinitis.954      JK Lee, et al. • The role of inhaled and/or nasal corticosteroids on the bronchodilator response
these two groups (P=0.733) and Δ%BDR showed no significant 
difference, either (P=0.714). 
In children with AR, prebronchodilator FEV1 was 93.7±11.3% 
and postbronchodilator FEV1 was 98.4±12.4% before treatment. 
Two weeks after starting treatment, their prebronchodilator FEV1 
was 94.3±13.7% and postbronchodilator FEV1 was 98.8%±14.5%. 
However, there was no meaningful change in prebronchodilator 
FEV1 (P=0.647) nor in postbronchodilator FEV1 (P=0.797) after 
medication with nasal FP. In these children, the BDR decreased 
from 5.0±3.0% to 4.7±3.3% after treatment, but the change was 
not statistically significant (P=0.597) (Fig. 2). In this study, 5 
children with AR alone showed obvious BDR (of ≥9%).
Discussion
We found that BDR were reduced after regular controller 
medication with FP in asthmatic patients regardless of combined 
AR. However, there were no significant changes in the BDR after 
regular application of nasal FP in the children with AR alone. 
In this study, asthmatic children without AR had a mean BDR of 
10.4±8.5%, and asthmatic children with AR showed a mean BDR 
of 9.1±5.9% at baseline. The BDR was elevated in both groups of 
children compared with our previous data (n=59; age, 10.3±2.6 
years; BDR, 3.3±2.2%) (P<0.001, one­way ANOVA). These 
findings correspond well with previous studies which reported 
elevated BDR in asthmatics
9­12). We found no significant difference 
in the BDR between asthmatics and the co­morbid subjects. To the 
best of our knowledge, however, there has been no other published 
data that has compared the BDR between these two groups. 
Previously, a few reports showed that there are no significant 
differences in prebronchodilator FEV1 or postbronchodilator FEV1 
between asthmatic patients with and without co­morbid AR
20,21). 
These reports may be partially in accordance with our finding. 
In adults, an increase in FEV1 of at least 12% from the baseline 
value or an absolute change of 200 mL is defined as a meaningful 
response
22). Previous reports have suggested that BDR over 9% 
would best distinguish children with asthma from those without 
asthma
10, 23). In this study, 33 (47%) of the 68 asthmatics and 18 
(40%) of the 45 asthmatics with AR showed a BDR of ≥9%.
In this study, the rhinitics had a mean BDR of 5.0±3.0% at 
baseline.  Although 5 (11%) of the 44 rhinitics showed a BDR of 
≥9%, the rhinitics as a group showed a higher BDR value than 
healthy population of 59 children in our previous study
14). Our 
finding is in good agreement with previous report of Capasso et 
al.
24), who showed a higher BDR in rhinitics than in normal control. 
However, they reported that more than 20% of rhinitics showed 
obvious BDR, which was a higher percentage in comparison with 
this study. Several factors such as the duration of AR, basal FEV1 
level and specific sensitization
13) should be considered to explain 
the discrepancy between the study and ours. Another explanation 
would be different dose of inhaled salbutamol in the bronchodilator 
testing. Previous study showed greater bronchodilator responses to 
inhalation of increasing doses of salbutamol
25).
An elevated BDR in children with AR may reflect co­exist  ­
ing bronchial inflammation
1­3). BDR is known to show a good 
correlation with biologic markers of lower airway inflammation
26, 
27). In this study, rhinitics showed a markedly lower BDR than 
asthmatics or asthmatics with AR. This also may be explained 
by the degree of lower airway inflammation in each condition. 
Previous studies which compared the degree of bronchial eosino­
philic inflammation between rhinitic patients and asthmatic 
patients reported a higher percentages of eosinophils and a higher 
levels of ECP in induced sputum from asthmatic patients than 
rhinitic patients
5, 28). 
Regardless of co­morbid AR, our children with asthma show­
ed a reduction in the BDR after regular use of FP. There were 
improvement in both prebronchodilator FEV1 and postbron­
chodilator FEV1 after regular treatment with FP. However, 
prebronchodilator FEV1 improved to a greater extent than post­
bronchodilator FEV1, causing of the reduction in BDR. Earlier 
reports showed reduction in the BDR with improvement of 
prebronchodilator FEV1 after treatment with inhaled FP
16, 17). The 
improvement in FEV1 would be associated with increased airway 
P<0.001
P=0.001
P=0.647
at abseline after treatment
Fig. 2. Prebronchodilator FEV1 at baseline and after treatment with 
inhaled and/or nasal FP. Prebronchodilator FEV1 increased after 
treatment in children with asthma, irrespective of whether or not 
they had comorbid AR. There was no significant change in the 
prebronchodilator FEV1 of children with AR alone. Abbreviations : FEV1, 
forced expiratory volume in one second; FP, fluticasone propionate; AR, 
allergic rhinitis.Korean J Pediatr 2010;53(11):951-956 • DOI: 10.3345/kjp.2010.53.11.951    955
caliber which was caused by anti­inflammatory effects of inhaled 
corticosteroids
16, 17, 29, 30). A reduction of inflammatory cells and a 
decrease in release of cytokines and mediators would reduce airway 
wall thickness ,airway secretions and muscle tones
15, 16, 30).
Nasal inflammation can influence the lower airway
2, 3). Many 
reports provide evidences to support that intranasal corticosteroids 
improve asthma symptoms and bronchial hyperresponsiveness in 
asthmatic patients with AR
31­33). However, in this study, adding 
intranasal FP to inhaled FP would seem to bring no additional 
effect on the BDR. Although children with co­morbid asthma and 
AR used both nasal and inhaled FP, but they showed similar degree 
of reduction in the BDR compared to those with asthma alone. 
Analogous results were found in previous studies
34, 35). There were 
no steroid sparing effect of intranasal corticosteroids when added to 
inhaled corticosteroids in the patients with both asthma and AR
35). 
Although combined treatment induced reduction of systemic 
eosinophilic inflammation in the study, there was no additional 
effect on improvement in methacholine PC20. 
In this study, it was an interesting finding that children with AR 
showed no definite changes in the BDR after regular treatment 
with nasal FP. A few studies have evaluated the effect of treatment 
with nasal corticosteroids on the biologic markers of lower airway 
inflammation. Sandrini et al.
36) have reported that no statistically 
significant effect of nasal corticosteroids on exhaled nitric oxide 
(ENO) in AR patients without asthma, while nasal corticosteroid 
meaningfully reduced ENO in the patients with co­morbid asthma 
and AR. Other study has reported that nasal corticosteroids 
improve the impaired FEF25­75 values in patients with AR
37). 
These discrepancies would be from that these two parameters 
reflect different aspects of the lower airway dysfunction. FEF25­
75 is considered as a marker of small airway obstruction, which 
may be a sensitive indicator of early bronchial impairment in 
AR
37, 38). Meanwhile, the BDR is known to reflect inflammations 
in the large airways
39). It may also be possible speculation that 
pretreatment BDR in AR group were not great enough to show 
definite changes after treatment. In this study, we could not find 
any significant change in BDR after treatment even in the subgroup 
of rhinitic children with BDR of ≥9% (n=5, P=0.094, Mann­
Whitney test). In addition, they showed no significant difference 
in prebronchodilator FEV1 at baseline period compared with other 
rhinitic children who did not show obvious BDR (P=0.782, Mann­
Whitney test). We cannot rule out the possibility of type II error 
due to the small sample size. It is possible that there is some effect of 
nasal corticosteroids on the BDR in subgroup of rhinitic children 
who have a markedly elevated BDR. If it was, such effect of nasal 
corticosteroids on the BDR may have been demonstrable in a larger 
number of patients. 
We evaluated the change of lung function after 2 weeks of 
treatment with inhaled and/or nasal FP. Previous study
29) reported 
that the improvement in BDR was near maximal after 2 weeks 
of treatment with inhaled FP. Furthermore, several studies
35,40) 
also demonstrated the marked improvement in nasal blockage, 
total nasal symptoms after 2 weeks of treatment with intranasal 
corticosteroids in rhinitic patients. 
In conclusion, we reported an elevated BDR in children with 
asthma and/or AR, and a significant reduction in the BDR 
after treatment with inhaled corticosteroids. Children with AR 
also showed a higher BDR than previously reported values in 
normal population, but they showed no significant changes in the 
BDR after treatment of nasal inflammation. This implies other 
physiologic factors in AR patients which induce elevated BDR 
besides their nasal inflammation.  
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